42 filings
Page 2 of 3
8-K
t5ar bcw8k8d2fj
12 Dec 22
IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100
7:53am
8-K
pw7x93wxc13
8 Dec 22
IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma
7:10am
8-K/A
kebu1z9woee blmzhwm
6 Dec 22
IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
4:06pm
8-K
8dq lnzfv4qqj
10 Nov 22
IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8:03am
8-K
3mvhibnasv2 qw0
13 Oct 22
Regulation FD Disclosure
8:44am
8-K
dztb07q4p
19 Aug 22
IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering
4:06pm
8-K
83ie1 dlppuyjp9
16 Aug 22
IN8bio Announces Pricing of
5:03pm
8-K
38jbx
12 Aug 22
IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:18pm
8-K
l7kfurkgaz l3dx
8 Aug 22
Results of Operations and Financial Condition
6:55am
8-K
6r1wbijhiaa
27 Jul 22
Other Events
8:00am
8-K
2mooqex 1u42y9
8 Jun 22
Regulation FD Disclosure
9:08am
8-K
cw3jd8zi0 al
2 Jun 22
Submission of Matters to a Vote of Security Holders
4:16pm
8-K
bun68
12 May 22
IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
8:19am
8-K
6uoxb9dipigdre
28 Mar 22
Other Events
8:10am
8-K
hjwkqd9pe uo8ju6
17 Mar 22
IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
4:23pm
8-K
wms l87uj
10 Jan 22
Regulation FD Disclosure
9:04am
8-K
mu4vuswzo3r1jresic
16 Dec 21
IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its
8:56am
8-K
asxtyr26
9 Dec 21
Departure of Directors or Certain Officers
4:40pm
8-K
zlvlvrup t0
17 Nov 21
Departure of Directors or Certain Officers
12:00am
8-K
x3c7dd2ondgvi pqhbh8
10 Nov 21
IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
4:31pm